Head-to-head · WeighScore
Cost Plus Drugs vs Omada Health
The verdict
Cost Plus Drugs takes it — 58.5/100 to 55.6/100.
Cost Plus Drugs grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mark Cuban's transparent-pricing online pharmacy.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cost Plus Drugs | Omada Health |
|---|---|---|
| WeighScore | 58.5/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #370 | #435 |
| Semaglutide | $279/mo (brand Ozempic) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #370 · C
Strengths
- Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
- Around $279/mo for branded Ozempic — well below typical retail list prices
- Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
- Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
- Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing
Where it loses points
- Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
- Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
- Wegovy availability has been spotty — check current stock before assuming it ships
- No compounded semaglutide or tirzepatide — brand only
- No clinical follow-up — side-effect monitoring falls to your prescribing clinician
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.